Achelois BioPharma develops curative, programmable Multivalent Therapeutics to treat cancer, viral infection, autoimmune, and inflammatory diseases. Unlike traditional drugs, which are designed to target a single molecule, multivalent therapeutics are designed to target a combination of molecules underlying complex human diseases.
Member, Scientific Advisory Board
Chairman, Scientific Advisory Board
Member, Scientific Advisory Board
Member, Scientific Advisory BoardDr. Colonno is an internationally recognized drug developer with over 40 years of experience in antiviral drug discovery and development. He recently served as Chief Science Officer at Assembly Bio and Presidio Pharmaceuticals, where he was responsible for providing scientific strategies, oversight, and direction for virology programs pursued, in addition to discovery, early development, and clinical support of novel antiviral agents. Prior to these experiences, he served as Vice President, Infectious Diseases Drug Discovery, at Bristol-Myers Squibb Co., and was instrumental in building and creating its antiviral franchise that led to the regulatory approval of the HBV nucleoside analog Baraclude (entecavir), the HIV protease inhibitor Reyataz (atazanavir), and HCV NS5A inhibitor ravidasvir. Dr. Colonno received a BA in Biology and Chemistry from Kansas Wesleyan University and a Ph.D. in Microbiology from the University of Kansas. He is internationally recognized as an expert in viral resistance and antiviral drug discovery, presented original research findings at numerous national and international meetings, and has co-authored more than 160 scientific articles.
Founder & CEO